| Literature DB >> 35010328 |
Houria El Ouazzani1,2,3, Simon Fortin1, Nicolas Venisse1,3,4, Antoine Dupuis1,2,3,4, Steeve Rouillon5, Guillaume Cambien1,2,4, Anne-Sophie Gourgues3, Pascale Pierre-Eugène1,2,4, Sylvie Rabouan1,2,4, Virginie Migeot1,2,3, Marion Albouy-Llaty1,2,3,4.
Abstract
Environmental health promotion interventions may reduce endocrine disruptor (ED) exposure. The PREVED (PREgnancy, preVention, Endocrine Disruptors) project was developed to improve knowledge, to enhance risk perception, and to change exposure behavior. Our objective was to present the phases of the PREVED project using the RE-AIM method. PREVED intervention consisted of three workshops during pregnancy. Reach, adoption, and implementation phases were assessed with qualitative studies. Efficacy study consisted of a three-arm randomized controlled trial (RCT) on 268 pregnant women: (i) control group (leaflet), (ii) intervention group in neutral location, (iii) intervention group in contextualized location. The main outcome was the percentage evolution of participants who reported consuming canned food. Secondary outcomes were evolution of psycho-social scores, evolution of ED presence in urine, and ED presence in colostrum. The intervention adoption was centered on upper-privileged women, but implementation assessment showed that key features (highly practical intervention) seemed to be carried out and had initiated some behavior changes. A total of 268 pregnant women participated in the intervention and 230 in a randomized controlled trial (control group: 86 and intervention groups: 172). We found no significant differences in consumption of canned food and in percentage of women having a decrease of bisphenol A or parabens in urine, but we found a significant increase in the evolution of risk perception score and overall psychosocial score in intervention groups (respectively: +15.73 control versus +21.03 intervention, p = 0.003 and +12.39 versus +16.20, p = 0.02). We found a significant difference in percentage of women with butylparaben detection between control group and intervention groups (13% versus 3%, p = 0.03). PREVED intervention is the first intervention research dedicated to perinatal environmental health education in France. By sharing know-how/experience in a positive non-alarmist approach, it improved risk perception, which is key to behavior change, aiming to reduce perinatal ED exposure. Including women in precarious situations remains a major issue.Entities:
Keywords: RE-AIM; bisphenol A; endocrine disruptors; environmental health promotion; lifestyle change intervention; parabens; pregnancy
Mesh:
Substances:
Year: 2021 PMID: 35010328 PMCID: PMC8750995 DOI: 10.3390/ijerph19010070
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Characteristics of PREVED cohort pregnant women.
| Control Group | Intervention Group | |||
|---|---|---|---|---|
| n1 | % | n2 | % | |
|
| ||||
| <30 | 14 | 17.9 | 29 | 19.1 |
| 30–34 | 35 | 44.9 | 73 | 40.0 |
| ≥35 | 29 | 37.2 | 50 | 32.9 |
| Mean; ±SD | 33.1 | ±4.3 | 32.8 | ±4.0 |
|
| ||||
| Married/Cohabiting/Civil partnership | 78 | 100.0 | 152 | 100.0 |
|
| ||||
| Nulliparous | 19 | 24.4 | 50 | 32.9 |
| 1 child | 25 | 32.1 | 60 | 39.5 |
| ≥2 children | 34 | 43.6 | 42 | 27.6 |
|
| ||||
| <18.5 | 4 | 5.1 | 13 | 8.6 |
| 18.5–25 | 59 | 75.6 | 112 | 73.7 |
| 25–30 | 13 | 16.7 | 21 | 13.8 |
| >30 | 2 | 2.6 | 6 | 3.9 |
| Mean; ±SD | 22.4 | ±3.2 | 22.6 | ±3.7 |
|
| ||||
| No | 11 | 14.1 | 8 | 5.3 |
| Yes | 67 | 85.9 | 141 | 92.7 |
|
| ||||
| None | 1 | 1.3 | 0 | 0.0 |
| Primary, secondary school (<12th grade) | 1 | 1.3 | 2 | 1.3 |
| Certificate of Professional Competence | 0 | 0.0 | 1 | 0.7 |
| French baccalaureate (12th grade) | 3 | 3.8 | 9 | 5.9 |
| French baccalaureate +2 (12–14th grade) | 10 | 12.8 | 22 | 14.5 |
| Higher education (>14th grade) | 59 | 75.6 | 112 | 73.7 |
| Other | 4 | 5.2 | 6 | 3.9 |
|
| ||||
| Metropolitan France | 70 | 89.7 | 144 | 94.7 |
| Overseas France | 2 | 2.6 | 0 | 0.0 |
| Other | 6 | 7.7 | 8 | 5.3 |
|
| ||||
| Precarious situation (≥30.17) | 8 | 10.3 | 22 | 14.5 |
| No precarious situation (<30.17) | 70 | 89.7 | 130 | 85.5 |
| Mean; ±SD | 8.3 | ±11.1 | 9.3 | ±12.2 |
Modifiable factors in the PREVED cohort pregnant women.
| Control Group | Temporal | Intervention Group | Temporal | |||
|---|---|---|---|---|---|---|
| n1 | % | n2 | % | |||
|
| ||||||
| | ||||||
| No | 64 | 82.1 | 0.26 | 113 | 74.3 |
|
| Yes | 14 | 17.9 | 39 | 25.7 | ||
| | ||||||
| No | 69 | 88.5 | 130 | 85.5 | ||
| Yes | 9 | 11.5 | 22 | 14.5 | ||
|
| ||||||
| | ||||||
| No | 4 | 5.1 |
| 25 | 16.4 |
|
| Yes | 74 | 94.9 | 127 | 83.6 | ||
| | ||||||
| Never | 69 | 94.5 | 124 | 84.4 | ||
| Very rarely | 4 | 5.5 | 20 | 13.6 | ||
| Once a month | 0 | 0.0 | 1 | 0.6 | ||
| Two or three times a month | 0 | 0.0 | 2 | 1.4 | ||
|
| ||||||
| | ||||||
| No | 24 | 30.8 |
| 43 | 28.3 |
|
| Yes | 54 | 69.2 | 109 | 71.7 | ||
| Mean; ±SD * (n1 = 54; n2 = 108) | 1.8 | ±1.7 | 1.8 | ±1.1 | ||
| | ||||||
| No | 46 | 59.0 | 84 | 55.3 | ||
| Yes | 32 | 41.0 | 68 | 44.7 | ||
| Mean; ±SD * (n1 = 32; n2 = 68) | 1.5 | ±0.8 | 1.7 | ±1.0 | ||
|
| ||||||
| | ||||||
| No | 39 | 50.0 |
| 66 | 43.4 |
|
| Yes | 39 | 50.0 | 86 | 56.6 | ||
| Mean; ±SD * (n1 = 39; n2 = 86) | 1.8 | ±1.9 | 2.2 | ±1.7 | ||
| | ||||||
| No | 58 | 74.4 | 92 | 60.5 | ||
| Yes | 20 | 25.6 | 60 | 39.5 | ||
| Mean; ±SD * (n1 = 21; n2 = 60) | 1.3 | ±0.6 | 1.8 | ±1.4 | ||
|
| ||||||
| | ||||||
| No | 18 | 23.1 |
| 28 | 18.4 |
|
| Yes | 60 | 76.9 | 124 | 81.6 | ||
| Mean; ±SD * (n1 = 59; n2 = 123) | 2.9 | ±2.9 | 2.3 | ±2.2 | ||
| | ||||||
| No | 35 | 44.9 | 55 | 36.2 | ||
| Yes | 43 | 55.1 | 97 | 63.8 | ||
| Mean; ±SD * (n1 = 43; n2 = 93) | 2.2 | ±1.9 | 2.0 | ±1.4 | ||
|
| ||||||
| |
| |||||
| Mean; ±SD * (n1 = 71; n2 = 142) | 4.7 | ±4.7 | 4.7 | ±3.8 |
| |
| | ||||||
| Mean; ±SD * (n1 = 59; n2 = 119) | 2.9 | ±2.3 | 3.4 | ±2.4 | ||
|
| ||||||
| | ||||||
| No | 66 | 84.6 | 0.97 | 124 | 81.6 | 0.37 |
| Yes | 12 | 15.4 | 28 | 18.4 | ||
| Mean; ±SD * (n1 = 13; n2 = 28) | 1.7 | ±1.7 | 1.5 | ±1.3 | ||
| | ||||||
| No | 65 | 84.4 | 129 | 85.4 | ||
| Yes | 12 | 15.6 | 22 | 14.6 | ||
| Mean; ±SD * (n1 = 12; n2 = 22) | 1.4 | ±0.7 | 1.7 | ±1.4 | ||
| Consumption of consumption of plastic drink bottles (/week) | ||||||
| | ||||||
| No | 45 | 57.7 | 0.52 | 79 | 52.0 | 0.68 |
| Yes | 33 | 42.3 | 73 | 48.0 | ||
| Mean; ±SD * (n1 = 33; n2 = 72) | 1.4 | ±1.1 | 1.4 | ±0.9 | ||
| | ||||||
| No | 41 | 52.6 | 82 | 54.3 | ||
| Yes | 37 | 47.4 | 69 | 54.7 | ||
| Mean; ±SD * (n1 = 37; n2 = 68) | 1.4 | ±1.1 | 1.5 | ±1.1 | ||
|
| ||||||
| Mean; ±SD | 4.0 | ±1.5 | 0.48 | 3.8 | ±1.3 | 0.31 |
| | ||||||
| Mean; ±SD | 4.3 | ±1.7 | 4.1 | ±1.3 | ||
|
| ||||||
| | ||||||
| No | 14 | 17.9 | 0.67 | 33 | 21.7 | 0.57 |
| Yes | 64 | 82.1 | 119 | 78.3 | ||
| | ||||||
| No | 12 | 15.4 | 29 | 19.1 | ||
| Yes | 66 | 84.6 | 123 | 80.1 | ||
|
| ||||||
| | ||||||
| No | 38 | 48.7 | 0.63 | 70 | 46.1 | 0.08 |
| Yes | 40 | 51.3 | 82 | 53.9 | ||
| Mean; ±SD * (n1 = 40; n2 = 82) | 1.6 | ±1.0 | 1.6 | ±0.9 | ||
| | ||||||
| No | 35 | 44.9 | 55 | 36.2 | ||
| Yes | 43 | 55.1 | 97 | 63.8 | ||
| Mean; ±SD * (n1 = 30; n2 = 73) | 1.53 | ±0.8 | 1.6 | ±1.3 | ||
|
| ||||||
| | ||||||
| No | 38 | 48.7 |
| 70 | 46.1 |
|
| Yes | 40 |
| 82 |
| ||
| Mean; ±SD * (n1 = 28; n2 = 39) | 1.5 | ±0.9 | 1.5 | ±1.2 | ||
| | ||||||
| No * (n1 = 40; n2 = 91) | 37 |
| 82 |
| ||
| Yes | 3 |
| 9 |
| ||
| Mean; ±SD * (n1 = 21; n2 = 23) | 1.5 | ±1.4 | 1.3 | ±0.8 | ||
* Missing data; SD: standard deviation. Significant results are bolded.
Adoption of the workshops in the PREVED study.
| Workshop1 | Workshop2 Food | Workshop3 Care Product | Total | |
|---|---|---|---|---|
| Total | 148 | 145 | 143 | 436 |
| Neutral location | 69 | 69 | 66 | 204 |
| Contextualized location | 79 | 76 | 77 | 232 |
| 2017 | 95 | 95 | 97 | 287 |
| 2018 | 36 | 35 | 32 | 103 |
| 2019 | 17 | 15 | 14 | 46 |
Figure 1Flow Chart–PREVED Study.
Consumption evolution. PREVED Study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| n1 | % | n2 | % | ||
|
| |||||
| Decrease | 34 | 57.6 | 72 | 65.4 | 0.47 |
| Stable | 9 | 27.1 | 21 | 19.1 | |
| Increase | 16 | 15.3 | 17 | 15.5 | |
|
| |||||
| No consumption in first visit and second visit | 19 | 24.4 | 41 | 27.0 | 0.10 |
| Consumption in first visit and no consumption in second visit | 27 | 34.6 | 43 | 28.3 | |
| Consumption in first visit and second visit | 27 | 34.6 | 66 | 43.4 | |
| No consumption in first visit and consumption in second visit | 5 | 6.4 | 2 | 1.3 | |
|
| |||||
| Decrease | 28 | 62.2 | 56 | 60.9 | 0.84 |
| Stable | 94 | 20.0 | 22 | 23.9 | |
| Increase | 8 | 17.8 | 14 | 15.2 | |
|
| |||||
| No consumption in first visit and second visit | 33 | 42.3 | 60 | 39.5 |
|
| Consumption in first visit and no consumption in second visit | 25 | 32.1 | 32 | 21.1 | |
| Consumption in first visit and second visit | 14 | 17.9 | 54 | 35.5 | |
| No consumption in first visit and consumption in second visit | 6 | 7.7 | 6 | 3.9 | |
|
| |||||
| Decrease | 38 | 56.7 | 66 | 50.4 | 0.69 |
| Stable | 15 | 22.4 | 35 | 26.7 | |
| Increase | 14 | 20.9 | 30 | 22.9 | |
|
| |||||
| No consumption in first visit and second visit | 10 | 12.8 | 20 | 13.1 | 0.15 |
| Consumption in first visit and no consumption in second visit | 25 | 32.0 | 35 | 23.0 | |
| Consumption in first visit and second visit | 35 | 44.9 | 89 | 58.6 | |
| No consumption in first visit and consumption in second visit | 8 | 10.3 | 8 | 5.3 | |
|
| |||||
| Decrease | 51 | 68.0 | 92 | 63.9 | 0.41 |
| Stable | 8 | 10.7 | 25 | 17.4 | |
| Increase | 16 | 21.3 | 27 | 18.7 | |
|
| |||||
| Decrease | 7 | 43.7 | 21 | 53.8 | 0.66 |
| Stable | 2 | 12.5 | 6 | 15.4 | |
| Increase | 7 | 43.7 | 12 | 30.8 | |
|
| |||||
| No consumption in first visit and second visit | 61 | 79.2 | 113 | 74.8 | 0.43 |
| Consumption in first visit and no consumption in second visit | 4 | 5.2 | 16 | 10.6 | |
| Consumption in first visit and second visit | 8 | 10.4 | 11 | 7.3 | |
| No consumption in first visit and consumption in second visit | 4 | 5.2 | 11 | 7.3 | |
|
| |||||
| Decrease | 11 | 23.9 | 27 | 30.0 | 0.76 |
| Stable | 20 | 43.5 | 36 | 40.0 | |
| Increase | 15 | 32.6 | 27 | 30.0 | |
|
| |||||
| No consumption in first visit and second visit | 32 | 41.0 | 60 | 39.7 | 0.71 |
| Consumption in first visit and no consumption in second visit | 9 | 11.5 | 22 | 14.6 | |
| Consumption in first visit and second visit | 24 | 30.8 | 51 | 33.8 | |
| No consumption in first visit and consumption in second visit | 13 | 16.7 | 18 | 11.9 | |
|
| |||||
| Decrease | 18 | 23.1 | 35 | 23.0 | 0.73 |
| Stable | 27 | 34.6 | 60 | 39.5 | |
| Increase | 33 | 42.3 | 57 | 37.5 | |
|
| |||||
| No consumption in first visit and second visit | 7 | 9.0 | 21 | 13.8 | 0.75 |
| Consumption in first visit and no consumption in second visit | 5 | 6.4 | 8 | 5.3 | |
| Consumption in first visit and second visit | 59 | 75.6 | 111 | 73.0 | |
| No consumption in first visit and consumption in second visit | 7 | 9.0 | 12 | 7.9 | |
|
| |||||
| Decrease | 17 | 40.5 | 32 | 34.8 | 0.09 |
| Stable | 22 | 52.4 | 39 | 42.4 | |
| Increase | 3 | 7.1 | 21 | 22.8 | |
|
| 0.7 | ||||
| No consumption in first visit and second visit | 35 | 44.9 | 61 | 40.1 | |
| Consumption in first visit and no consumption in second visit | 12 | 15.4 | 19 | 12.5 | |
| Consumption in first visit IT and second visit | 28 | 35.9 | 63 | 41.4 | |
| No consumption in first visit and consumption in second visit | 3 | 3.9 | 9 | 5.9 | |
|
| |||||
| Decrease | 13 | 43.3 | 30 | 60.0 | 0.35 |
| Stable | 11 | 36.7 | 8 | 16.0 | |
| Increase | 6 | 20.0 | 12 | 24.0 | |
|
| |||||
| No consumption in first visit and second visit | 47 | 61.0 | 101 | 66.9 |
|
| Consumption in first visit and no consumption in second visit | 2 | 2.6 | 11 | 2.3 | |
| Consumption in first visit and second visit | 19 | 24.7 | 14 | 9.3 | |
| No consumption in first visit and consumption in second visit | 2 | 2.6 | 11 | 7.3 | |
* Missing data. Significant results are bolded.
Psychosocial variables (Intention-to-treat analysis) in PREVED Study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| Δm * | IC 95% | Δm * | IC 95% | ||
|
| +3.55 | [+2.68; +4.42] | +3.40 | [+2.88; +3.90] | 0.75 |
| Sources of exposure to endocrine-disrupting chemicals (score/22) | +2.15 | [+1.48; +2.82] | +1.97 | [+1.54; +2.40] | 0.64 |
| Definition of endocrine disruptors (score/7) | +0.44 | [+0.16; +0.71] | +0.36 | [+0.20; +0.52] | 0.63 |
| Ability to name molecules (score/6.5) | +0.77 | [+0.54; +1.00] | +0.83 | [+0.66; +0.99] | 0.69 |
| Pathways of exposure to endocrine Disrupting chemicals (score/5) | +0.19 | [+0.07; +0.31] | +0.23 | [+0.15; +0.31] | 0.59 |
|
| +7.09 | [+2.33; +11.85] | +5.11 | [+1.80; +8.42] | 0.50 |
|
| +20.21 | [+16.19; +24.23] | +19.20 | [+15.77; +22.63] | 0.72 |
| The health of pregnant women | +7.16 | [+1.40; +12.91] | +7.61 | [+3.28; +11.94] | 0.90 |
| The newborn health | +8.09 | [+2.28; +8.54] | +5.41 | [+2.28; +8.54] | 0.31 |
| The adolescent health | +7.56 | [+3.50; +11.63] | +4.73 | [+2.05; +7.41] | 0.24 |
| The adult health | +6.06 | [+1.38; +10.74] | +4.47 | [+0.87; +8.08] | 0.60 |
|
| |||||
| Perceived vulnerability score/1400 | +275.60 | [+229.20; +322.00] | +256.40 | [+228.60; +284.20] | 0.46 |
| Perceived vulnerability score/100 | +19.69 | [+16.37; +23.00] | +18.31 | [+16.33; +20.30] | 0.46 |
|
| +19.50 | [+17.12; +22.78] | +18.76 | [+16.68; +20.84] | 0.51 |
|
| +15.63 | [+13.21; +18.05] | +14.45 | [+13.00; +15.91] | 0.38 |
|
| +28.24 | [+24.23; +32.26] | +19.77 | [+16.51; +23.03] |
|
|
| |||||
| Understandable * (n = 74; 142) | −1.65 | [−8.33; +5.03] | −1.35 | [−6.14; +3.45] | 0.99 |
| Scientific * (n = 74; 142) | −2.39 | [−7.39; +2.61] | +2.15 | [−0.87; +5.18] | 0.10 |
| Realistic * (n = 74; 142) | +3.96 | [−1.01; +8.93] | −0.36 | [−3.85; +3.12] | 0.15 |
| Stressful * (n = 74; 142) | −1.91 | [−6.05; +2.24] | −3.34 | [−5.80; −0.88] | 0.53 |
| Complete * (n = 73; 142) | +6.30 | [−0.18; +12.78] | +11.70 | [+7.72; +15.68] | 0.14 |
|
| |||||
| Pregnancy pain | −7.13 | [−13.09; −1.17] | −0.93 | [−5.07; +3.22] | 0.09 |
| The consequences of consumption of toxic substances for the child * (n = 77; 151) | +1.64 | [−7.16; +10.43] | +1.18 | [−4.61; +6.97] | 0.93 |
| Infectious diseases * (n = 76; 152) | −8.25 | [−14.79; −1.71] | −6.80 | [−11.53; −2.07] | 0.72 |
| Genetic diseases | −5.5 | [−11.60; +0.50] | −5.48 | [−9.63; −1.33] | 0.98 |
| Child illnesses linked to chemical exposure | −1.73 | [−7.31; +3.85] | +0.22 | [−3.06; +3.50] | 0.52 |
|
| |||||
| Healthy birth weight* (n = 78; 151) | +5.21 | [−0.63; +11.04] | −3.25 | [−7.75; +1.25] |
|
| Full-term birth | +3.05 | [−3.05; +9.15] | −1.47 | [−5.51; +2.56] | 0.21 |
| Normal intelligence quotient (IQ) | +6.08 | [−0.60; +12.75] | +6.19 | [+1.76; +10.63] | 0.98 |
| Ability to have children | +7.50 | [+1.18; +13.82] | +1.91 | [−1.70; +5.51] | 0.13 |
| Normal puberty | +4.73 | [+0.19; +9.27] | +1.64 | [−2.15; +5.44] | 0.33 |
| Normal weight (no obesity; no overweight) | +1.24 | [−2.80; +5.28] | +0.37 | [−3.51; +4.24] | 0.76 |
| No asthma | +3.36 | [−0.91; +7.63] | +0.96 | [−3.06; +4.98] | 0.42 |
| No behavior disorders | +3.69 | [−1.50; +8.89] | +4.64 | −[+0.41; +8.87] | 0.79 |
| Can play like all the other children | −1.14 | [−6.57; +4.28] | −0.21 | [−4.47; +4.05] | 0.80 |
| Not get sick so often | +3.03 | [−2.16; +8.22] | +0.05 | [−4.18; +4.28] | 0.40 |
| Able to make friends and fit in | −0.99 | [−6.32; +4.34] | +5.54 | [+1.54; +9.53] | 0.06 |
| Successful professional life | +0.53 | [−5.12; +6.17] | +5.96 | [+1.94; +9.98] | 0.12 |
| Successful emotional life | −1.35 | [−7.03; +4.33] | +5.32 | [+1.59; 9.05] |
|
|
| |||||
| Financially | −2.30 | [−7.25; +2.63] | +0.40 | [−2.76; +3.57] | 0.34 |
| In terms of time * (n = 77; 152) | +6.36 | [+0.98; +11.75] | +3.11 | [−0.40; +6.62] | 0.30 |
| In terms of comfort * (n = 77; 152) | −1.00 | [−8.12; +6.12] | −2.05 | [−6.12; +2.03] | 0.79 |
|
| |||||
| Internal locus of control (score/6) | +0.02 | [−0.03; +0.08] | −0.03 | [−0.07; +0.01] | 0.11 |
| External locus of control: chance (score/3) | −0.01 | [−0.10; +0.08] | +0.01 | [−0.05; +0.06] | 0.83 |
| External locus of control: medical personnel (score/4) | +0.06 | [−0.02; +0.14] | −0.03 | [−0.08; +0.02] | 0.06 |
|
| |||||
| Comprehensive (score/5) | −0.06 | [−0.24; +0.13] | +0.06 | [−0.07; +0.19] | 0.28 |
| Meaningful (score/4) | −0.03 | [−0.18; +0.13] | +0.02 | [−0.11; +0.14] | 0.67 |
| Manageable (score/4) | −0.16 | [−0.32; +0.01] | −0.09 | [−0.20; +0.03] | 0.46 |
|
| +0.56 | [−0.05; +1.18] | +0.49 | [+0.01; 0.96] | 0.85 |
|
| −3.74 | [−7,65; +0.16] | −1.05 | [−3.66; +1.56] | 0.25 |
|
| −6.65 | [−12.35; −0.96] | −4.76 | [−8.93; −0.60] | 0.60 |
|
| |||||
| Professional life | −2.62 | [−7.40; +2.17] | −1.63 | [−5.19; +1.94] | 0.75 |
| Sport activities | +3.81 | [+0.42; +7.20] | −0.09 | [−3.02; +2.83] | 0.11 |
| Sexual practices | +1.26 | [−1.34; +3.85] | +0.97 | [−1.25; +3.20] | 0.88 |
| Road traffic | −0.81 | [−3.84; +2.22] | +2.24 | [−0.57; +5.05] | 0.15 |
| Use of substance | +0.82 | [−2.10; +3.74] | −0.15 | [−2.56; +2.26] | 0.63 |
* Δm: mean difference between first and second visit. Significant results are bolded.
Urine biomarkers and exposition: Univariate analysis between 2nd (first visit) and 3rd trimester (second visit) (intent-to-treat analysis) in PREVED study.
| Control Group (n = 80) | Intervention Group (n = 145) |
| |||
|---|---|---|---|---|---|
| N | % | N | % | ||
|
| |||||
| Rising indicator | 25 | 31 | 47 | 32 | |
| Same indicator | 34 | 43 | 63 | 44 | 0.94 |
| Decline indicator | 21 | 26 | 35 | 24 | |
|
| |||||
| Rising indicator | 15 | 19 | 34 | 23 | |
| Same indicator | 48 | 60 | 67 | 46 | 0.13 |
| Decline indicator | 17 | 21 | 44 | 31 | |
|
| |||||
| Rising indicator | 22 | 27 | 37 | 26 | |
| Same indicator | 39 | 49 | 75 | 52 | 0.91 |
| Decline indicator | 19 | 24 | 33 | 22 | |
|
| |||||
| Rising indicator | 13 | 16 | 22 | 15 | |
| Same indicator | 55 | 69 | 99 | 68 | 0.94 |
| Decline indicator | 12 | 15 | 24 | 17 | |
|
| |||||
| Rising indicator | 14 | 17 | 22 | 15 | |
| Same indicator | 47 | 59 | 88 | 61 | 0.90 |
| Decline indicator | 19 | 24 | 35 | 24 | |
|
| |||||
| Rising indicator | 15 | 19 | 28 | 19 | |
| Same indicator | 50 | 62 | 71 | 49 | 0.08 |
| Decline indicator | 15 | 19 | 46 | 32 | |
|
| |||||
| Rising indicator | 22 | 27 | 29 | 20 | |
| Same indicator | 35 | 44 | 59 | 41 | 0.22 |
| Decline indicator | 23 | 29 | 57 | 39 | |
|
| |||||
| Rising indicator | 8 | 10 | 22 | 15 | |
| Same indicator | 62 | 78 | 99 | 68 | 0.33 |
| Decline indicator | 10 | 12 | 24 | 17 | |
|
| |||||
| Rising indicator | 2 | 3 | 2 | 1 | |
| Same indicator | 77 | 96 | 139 | 96 | 0.64 |
| Decline indicator | 1 | 1 | 4 | 3 | |
Univariate analysis after data imputation (intent-to-treat analysis) in the PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| Mean (ng/mL) |
| Mean (ng/mL) |
| ||
| LoQ divides by two (LoQ/2) | |||||
|
| |||||
| Second trimester (urine) | 15.8 | 86 | 13.6 | 171 | 0.85 |
| Third trimester (urine) | 7 | 80 | 14.8 | 146 | 0.69 |
| Birth (colostrum) | 0.28 | 39 | 0.21 | 88 | 0.27 |
| One Year (urine) | 3 | 35 | 0.4 | 72 | 0.27 |
|
| |||||
| Birth (colostrum) | 1.16 | 45 | 1 | 102 | 0.99 |
| Truncation k-Nearest Neighbor (kNN-TN) | |||||
|
| |||||
| Second trimester (urine) | 16 | 86 | 13.8 | 171 | 0.86 |
| Third trimester (urine) | 6.8 | 80 | 14.3 | 146 | 0.08 |
| Birth (colostrum) | 0.3 | 39 | 0.27 | 88 | 0.38 |
| One year (urine) | 1.4 | 35 | 0.4 | 72 | 0.29 |
|
| |||||
| Birth (colostrum) | 1.53 | 45 | 1.21 | 102 |
|
Significant results are bolded.
Consumption and psychosocial variables (per-protocol analysis) in the PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| N |
| N |
| ||
|
| |||||
|
| |||||
| Decrease | 40 | 65.6 | 66 | 61.1 | 0.83 |
| Stable | 12 | 19.7 | 25 | 23.2 | |
| Increase | 9 | 14.7 | 26 | 15.7 | |
|
| |||||
| Decrease | 27 | 60.0 | 57 | 62.0 | 0.94 |
| Stable | 11 | 24.4 | 20 | 21.7 | |
| Increase | 7 | 15.6 | 15 | 16.3 | |
|
| |||||
| Decrease | 41 | 58.6 | 63 | 49.2 | 0.44 |
| Stable | 15 | 21.4 | 35 | 27.4 | |
| Increase | 14 | 20.00 | 30 | 23.4 | |
|
| |||||
| Decrease | 50 | 66.8 | 93 | 65.0 | 0.94 |
| Stable | 12 | 15.8 | 21 | 14.7 | |
| Increase | 14 | 18.4 | 29 | 20.3 | |
|
| |||||
| Decrease | 13 | 61.9 | 15 | 44.1 | 0.05 |
| Stable | 0 | 0.0 | 8 | 23.5 | |
| Increase | 8 | 38.1 | 11 | 32.4 | |
|
| |||||
| Decrease | 15 | 30.6 | 23 | 26.4 | 0.85 |
| Stable | 20 | 40.8 | 36 | 41.4 | |
| Increase | 14 | 28.6 | 28 | 32.2 | |
|
| |||||
| Decrease | 21 | 25.9 | 32 | 21.5 | 0.67 |
| Stable | 31 | 38.3 | 56 | 37.6 | |
| Increase | 29 | 35.8 | 61 | 40.9 | |
|
| |||||
| Decrease | 16 | 33.3 | 33 | 38.4 | 0.12 |
| Stable | 19 | 39.6 | 42 | 48.8 | |
| Increase | 13 | 27.1 | 11 | 12.8 | |
|
| |||||
| Decrease | 15 | 57.7 | 28 | 51.8 | 0.45 |
| Stable | 4 | 15.4 | 15 | 27.8 | |
| Increase | 7 | 26.9 | 11 | 20.4 | |
|
| |||||
| 1-Endocrine-disrupting chemicals knowledge (score/40.5) ** | +3.22 | [+2.52; +3.93] | +3.57 | [+2.99; +4.14] | 0.47 |
| 2-Perceived ability to avoid chemical exposure (/100) ** | +7.09 | [+2.33; +11.85] | +5.11 | [+1.80; +8.42] | 0.50 |
| 3-Risk from endocrine-disrupting chemicals (severity score/100) ** | +15.61 | [+10.64; 20.58] | +21.69 | [+18.67; +24.70] |
|
| 4-Risk assessment of endocrine-disrupting chemicals (vulnerability score/1400) ** | +222.00 | [+187.00; +257.10] | +285.10 | [+253.60; +316.6] |
|
|
| +15.73 | [+12.96; +18.51] | +21.03 | [+18.99; +23.07] |
|
|
| +12.39 | [+10.57; +14.21] | +16.2 | [+14.55; +17.83] |
|
* Missing data ** Δm: mean difference CI: Confidence Interval. Significant results are bolded.
Consumption and psychosocial variables by groups (per protocol analysis) in the PREVED study.
| 0 or 1 Workshop | 2 or 3 Workshops in Neutral Location | 2 or 3 Workshops in Contextualized Location |
| ||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
|
| |||||||
|
| |||||||
| Decrease | 42 | 64.6 | 29 | 65.9 | 33 | 57.9 | 0.90 |
| Stable | 14 | 21.5 | 8 | 18.2 | 14 | 24.6 | |
| Increase | 9 | 13.9 | 7 | 15.9 | 10 | 17.5 | |
|
| |||||||
| Decrease | 28 | 58.3 | 26 | 59.1 | 29 | 67.4 | 0.63 |
| Stable | 13 | 27.1 | 11 | 25.0 | 6 | 14.0 | |
| Increase | 7 | 14.6 | 7 | 15.9 | 8 | 18.6 | |
|
| |||||||
| Decrease | 46 | 56.8 | 20 | 38.5 | 36 | 57.1 | 0.16 |
| Stable | 16 | 19.7 | 19 | 36.5 | 15 | 23.8 | |
| Increase | 19 | 23.5 | 13 | 25.0 | 12 | 19.1 | |
|
| |||||||
| Decrease | 55 | 63.2 | 37 | 63.8 | 48 | 67.6 | 0.60 |
| Stable | 13 | 14.9 | 12 | 29.7 | 8 | 11.3 | |
| Increase | 19 | 21.8 | 9 | 15.5 | 15 | 21.1 | |
|
| |||||||
| Decrease | 13 | 59.1 | 6 | 37.5 | 8 | 50.0 |
|
| Stable | 0 | 0.0 | 6 | 37.5 | 2 | 12.5 | |
| Increase | 9 | 40.9 | 4 | 25.0 | 6 | 37.5 | |
|
| |||||||
| Decrease | 16 | 29.1 | 9 | 26.5 | 12 | 27.3 | 0.94 |
| Stable | 21 | 38.2 | 16 | 47.1 | 18 | 40.9 | |
| Increase | 18 | 32.7 | 9 | 26.5 | 14 | 31.8 | |
|
| |||||||
| Decrease | 25 | 27.2 | 11 | 18.3 | 16 | 21.3 | 0.68 |
| Stable | 35 | 38.0 | 24 | 40.0 | 27 | 36.0 | |
| Increase | 32 | 34.8 | 25 | 41.7 | 32 | 42.7 | |
|
| |||||||
| Decrease | 19 | 34.6 | 15 | 39.5 | 13 | 34.2 |
|
| Stable | 18 | 32.7 | 19 | 50.0 | 23 | 60.5 | |
| Increase | 18 | 32.7 | 4 | 10.5 | 2 | 5.3 | |
|
| |||||||
| Decrease | 19 | 59.4 | 13 | 59.1 | 11 | 44.0 | 0.07 |
| Stable | 4 | 12.5 | 4 | 18.2 | 11 | 44.0 | |
| Increase | 9 | 28.1 | 5 | 22.7 | 3 | 12.0 | |
|
| |||||||
|
| +16.18 | [−24.23; +58.45] | +20.27 | [−16.00; +48.37] | +21.41 | [−9.15; +56.52] |
|
|
| +12.7 | [−14.3; +42.6] | +16.0 | [−6.9; +38.0] | +16.4 | [−13.1; +45.5] |
|
* Missing data ** Δm: mean difference CI: Confidence Interval. Significant results are bolded.
Colostrum biomarkers and exposition in univariate analysis, intervention group with at least two workshop (per protocol analysis) in the PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| N | % | N | % | ||
|
| |||||
| Superior to LoD | 42 | 75 | 71 | 78 | 0.67 |
| Inferior to LoD | 14 | 25 | 20 | 22 | |
|
| |||||
| Superior to LoD | 23 | 41 | 44 | 48 | 0.39 |
| Inferior to LoD | 33 | 59 | 47 | 52 | |
|
| |||||
| Superior to LoD | 26 | 46 | 43 | 47 | 0.92 |
| Inferior to LoD | 30 | 54 | 48 | 53 | |
|
| |||||
| Superior to LoD | 39 | 70 | 56 | 62 | 0.32 |
| Inferior to LoD | 17 | 30 | 35 | 38 | |
|
| |||||
| Superior to LoD | 29 | 52 | 46 | 51 | 0.88 |
| Inferior to LoD | 27 | 48 | 45 | 49 | |
|
| |||||
| Superior to LoD | 44 | 92 | 68 | 86 | 0.34 |
| Inferior to LoD | 4 | 8 | 11 | 14 | |
|
| |||||
| Superior to LoD | 31 | 65 | 45 | 57 | 0.40 |
| Inferior to LoD | 17 | 35 | 34 | 43 | |
|
| |||||
| Superior to LoD | 14 | 29 | 25 | 32 | 0.77 |
| Inferior to LoD | 34 | 71 | 54 | 68 | |
|
| |||||
| Superior to LoD | 6 | 13 | 1 | 1 |
|
| Inferior to LoD | 42 | 87 | 78 | 99 | |
LoD: Limit of Detection. Significant results are bolded.
Urine biomarkers and exposure n, univariate analysis between 2nd (first visit) and 3rd trimester (second visit), intervention group with at least one workshop (per protocol analysis) in the PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| n | % | n | % | ||
|
| |||||
| Rising indicator | 28 | 32 | 44 | 32 | |
| Same indicator | 38 | 43 | 59 | 43 | 0.76 |
| Decline indicator | 22 | 25 | 34 | 25 | |
|
| |||||
| Rising indicator | 16 | 18 | 33 | 24 | |
| Same indicator | 51 | 58 | 64 | 47 | 0.25 |
| Decline indicator | 21 | 24 | 40 | 29 | |
|
| |||||
| Rising indicator | 22 | 25 | 37 | 27 | |
| Same indicator | 44 | 50 | 70 | 51 | 0.85 |
| Decline indicator | 22 | 25 | 30 | 22 | |
|
| |||||
| Rising indicator | 15 | 17 | 20 | 14 | |
| Same indicator | 60 | 68 | 94 | 69 | 0.84 |
| Decline indicator | 13 | 15 | 23 | 17 | |
|
| |||||
| Rising indicator | 15 | 17 | 21 | 15 | |
| Same indicator | 51 | 58 | 84 | 61 | 0.88 |
| Decline indicator | 22 | 25 | 32 | 24 | |
|
| |||||
| Rising indicator | 17 | 19 | 26 | 19 | |
| Same indicator | 55 | 63 | 66 | 48 |
|
| Decline indicator | 16 | 18 | 45 | 33 | |
|
| |||||
| Rising indicator | 22 | 25 | 29 | 22 | |
| Same indicator | 40 | 45 | 54 | 39 | 0.32 |
| Decline indicator | 26 | 30 | 54 | 39 | |
|
| |||||
| Rising indicator | 10 | 11 | 20 | 15 | |
| Same indicator | 69 | 79 | 92 | 67 | 0.16 |
| Decline indicator | 9 | 10 | 25 | 18 | |
|
| |||||
| Rising indicator | 2 | 2 | 2 | 1 | |
| Same indicator | 85 | 97 | 131 | 96 | 0.66 |
| Decline indicator | 1 | 1 | 4 | 3 | |
Significant results are bolded.
Colostrum biomarkers and exposure in univariate analysis, intervention group with at least one workshop (per protocol analysis) PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| N | % | N | % | ||
|
| |||||
| Superior to LoD | 39 | 76 | 74 | 77 | 0.93 |
| Inferior to LoD | 12 | 24 | 22 | 23 | |
|
| |||||
| Superior to LoD | 21 | 41 | 46 | 48 | 0.43 |
| Inferior to LoD | 30 | 59 | 50 | 52 | |
|
| |||||
| Superior to LoD | 25 | 49 | 44 | 46 | 0.71 |
| Inferior to LoD | 26 | 51 | 52 | 54 | |
|
| |||||
| Superior to LoD | 34 | 67 | 61 | 64 | 0.71 |
| Inferior to LoD | 17 | 33 | 35 | 36 | |
|
| |||||
| Superior to LoD | 25 | 49 | 50 | 52 | 0.72 |
| Inferior to LoD | 26 | 51 | 46 | 48 | |
|
| |||||
| Superior to LoD | 41 | 93 | 71 | 86 | 0.32 |
| Inferior to LoD | 3 | 7 | 12 | 14 | |
|
| |||||
| Superior to LoD | 30 | 68 | 46 | 55 | 0.16 |
| Inferior to LoD | 14 | 32 | 37 | 45 | |
|
| |||||
| Superior to LoD | 13 | 30 | 26 | 31 | 0.84 |
| Inferior to LoD | 31 | 70 | 57 | 69 | |
|
| |||||
| Superior to LoD | 6 | 14 | 1 | 1 |
|
| Inferior to LoD | 38 | 86 | 82 | 99 | |
LoD: Limit of Detection. Significant results are bolded.
Urine biomarkers and exposure: Univariate analysis between 2nd trimester (first visit) and one year (intent-to-treat analysis) in the PREVED study.
| Control Group | Intervention Group | ||||
|---|---|---|---|---|---|
| N |
| N |
|
| |
|
| |||||
| Rising indicator | 11 | 32 | 14 | 19 | |
| Same indicator | 11 | 32 | 36 | 50 | 0.16 |
| Decline indicator | 13 | 36 | 22 | 31 | |
|
| |||||
| Rising indicator | 5 | 14 | 11 | 15 | |
| Same indicator | 18 | 52 | 23 | 32 | 0.14 |
| Decline indicator | 12 | 34 | 38 | 53 | |
|
| |||||
| Rising indicator | 2 | 6 | 7 | 9 | |
| Same indicator | 21 | 60 | 40 | 56 | 0.77 |
| Decline indicator | 12 | 34 | 25 | 35 | |
|
| |||||
| Rising indicator | 3 | 9 | 2 | 3 | |
| Same indicator | 25 | 71 | 56 | 78 | 0.40 |
| Decline indicator | 7 | 20 | 14 | 19 | |
|
| |||||
| Rising indicator | 9 | 26 | 9 | 13 | |
| Same indicator | 21 | 60 | 44 | 61 | 0.14 |
| Decline indicator | 5 | 14 | 19 | 26 | |
|
| |||||
| Rising indicator | 12 | 34 | 17 | 24 | |
| Same indicator | 17 | 49 | 23 | 32 |
|
| Decline indicator | 6 | 17 | 32 | 44 | |
|
| |||||
| Rising indicator | 15 | 43 | 20 | 28 | |
| Same indicator | 11 | 31 | 37 | 51 | 0.14 |
| Decline indicator | 9 | 26 | 15 | 21 | |
|
| |||||
| Rising indicator | 4 | 12 | 15 | 21 | |
| Same indicator | 25 | 71 | 47 | 65 | 0.48 |
| Decline indicator | 6 | 17 | 10 | 14 | |
|
| |||||
| Rising indicator | 2 | 5 | 3 | 4 | |
| Same indicator | 32 | 92 | 66 | 92 | 0.89 |
| Decline indicator | 1 | 3 | 3 | 4 | |
Significant results are bolded.
Urine biomarkers and exposure: Univariate analysis between 2nd trimester (first visit) and one year, intervention group with at least two workshops (per protocol analysis) in the PREVED study.
| Control Group | Intervention Group |
| |||
|---|---|---|---|---|---|
| N |
| N |
| ||
|
| |||||
| Rising indicator | 12 | 28 | 13 | 20 | |
| Same indicator | 16 | 37 | 31 | 49 | 0.48 |
| Decline indicator | 15 | 35 | 20 | 31 | |
|
| |||||
| Rising indicator | 6 | 14 | 10 | 16 | |
| Same indicator | 20 | 46 | 21 | 33 | 0.35 |
| Decline indicator | 17 | 40 | 33 | 51 | |
|
| |||||
| Rising indicator | 3 | 7 | 6 | 10 | |
| Same indicator | 25 | 58 | 36 | 56 | 0.91 |
| Decline indicator | 15 | 35 | 22 | 34 | |
|
| |||||
| Rising indicator | 3 | 7 | 2 | 3 | |
| Same indicator | 32 | 74 | 49 | 77 | 0.65 |
| Decline indicator | 8 | 19 | 13 | 20 | |
|
| |||||
| Rising indicator | 9 | 21 | 9 | 14 | |
| Same indicator | 27 | 63 | 38 | 59 | 0.37 |
| Decline indicator | 7 | 16 | 17 | 27 | |
|
| |||||
| Rising indicator | 14 | 33 | 15 | 23 | |
| Same indicator | 19 | 44 | 21 | 33 | 0.09 |
| Decline indicator | 10 | 23 | 28 | 44 | |
|
| |||||
| Rising indicator | 19 | 44 | 16 | 25 | |
| Same indicator | 13 | 30 | 35 | 55 |
|
| Decline indicator | 11 | 26 | 13 | 20 | |
|
| |||||
| Rising indicator | 4 | 10 | 15 | 23 | |
| Same indicator | 32 | 74 | 40 | 63 | 0.17 |
| Decline indicator | 7 | 16 | 9 | 14 | |
|
| |||||
| Rising indicator | 2 | 4 | 3 | 5 | |
| Same indicator | 40 | 94 | 58 | 90 | 0.82 |
| Decline indicator | 1 | 2 | 3 | 5 | |
Significant results are bolded.